324 related articles for article (PubMed ID: 22797065)
1. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.
Krajewska M; Heijink AM; Bisselink YJ; Seinstra RI; Silljé HH; de Vries EG; van Vugt MA
Oncogene; 2013 Jun; 32(24):3001-8. PubMed ID: 22797065
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
4. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
5. Targeting Wee1-like protein kinase to treat cancer.
Stathis A; Oza A
Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
[TBL] [Abstract][Full Text] [Related]
6. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery.
Chow JP; Poon RY
Oncogene; 2013 Oct; 32(40):4778-88. PubMed ID: 23146904
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
8. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
9. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
11. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang Y; Li J; Booher RN; Kraker A; Lawrence T; Leopold WR; Sun Y
Cancer Res; 2001 Nov; 61(22):8211-7. PubMed ID: 11719452
[TBL] [Abstract][Full Text] [Related]
14. Fission yeast wee1 protein kinase is not required for DNA damage-dependent mitotic arrest.
Barbet NC; Carr AM
Nature; 1993 Aug; 364(6440):824-7. PubMed ID: 8355807
[TBL] [Abstract][Full Text] [Related]
15. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
Matheson CJ; Casalvieri KA; Backos DS; Reigan P
ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
17. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins.
Knight GL; Turnell AS; Roberts S
J Virol; 2006 Aug; 80(15):7416-26. PubMed ID: 16840322
[TBL] [Abstract][Full Text] [Related]
18. Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality.
Szmyd R; Niska-Blakie J; Diril MK; Renck Nunes P; Tzelepis K; Lacroix A; van Hul N; Deng LW; Matos J; Dreesen O; Bisteau X; Kaldis P
Oncogene; 2019 Feb; 38(7):998-1018. PubMed ID: 30190546
[TBL] [Abstract][Full Text] [Related]
19. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
[TBL] [Abstract][Full Text] [Related]
20. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.
Aarts M; Bajrami I; Herrera-Abreu MT; Elliott R; Brough R; Ashworth A; Lord CJ; Turner NC
Mol Cancer Ther; 2015 Apr; 14(4):865-76. PubMed ID: 25673822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
